TABLE 3.

Phenotyping of 4 env controls and 49 env isolates from 19 samples

Sample	Clone	FPR (%)	Infectivity vs that for no-drug control (%)			Phenotype	Description
			Maraviroc	AMD3100	AMD3100 + maraviroc
BAL	NA	24.7	0.18	66.18	0.11	R5	Control
JR-CSF	NA	31.7	1.73	92.57	0.28	R5	Control
BV-5002	NA	2.0	145.64	0.80	0.03	X4	Control
NL43	NA	2.0	145.36	0.10	0.13	X4	Control
C01	B7	56.5	0.81	159.62	1.26	R5
	D11	42.7	0.35	177.87	0.47	R5
C02	A10	38.0	0.80	84.05	0.55	R5
	F9	38.0	0.18	62.28	0.17	R5
C03	D11	68.6	0.20	75.55	0.22	R5
	E8	68.6	0.05	61.10	0.05	R5
C04	D11	2.6	0.31	141.78	0.68	R5
	F4	2.9	0.08	63.45	0.12	R5
	G1	2.7	0.08	103.96	0.24	R5
	G10	6.9	0.77	91.48	0.30	R5
	G2	0.7	84.34	39.04	0.40	Dual
C05	C4	64.0	0.22	103.64	0.17	R5
	E4	1.7	94.55	67.94	27.44	Dual
C06	A7	21.8	18.62	122.43	27.50	R5
	D1	24.7	16.40	76.27	6.81	R5
	D10	24.7	15.43	96.58	9.94	R5
	E6	0.5	88.37	64.79	39.04	Dual
C07	C11	1.7	102.89	42.17	3.19	Dual
	C8	5.0	1.58	123.26	0.56	R5
	F5	5.0	0.77	124.26	0.17	R5
C08	F9	0.5	88.57	0.06	0.10	X4
	H12	0.5	158.23	3.70	0.17	X4
C09	A4	1.1	123.05	50.92	0.42	Dual
	D1	4.8	4.66	57.93	0.28	Dual
	E6	4.8	23.60	38.31	0.12	Dual
	G5	11.4	1.34	75.12	0.87	R5
C10	D9	0.0	133.23	1.39	1.58	X4
	G4	67.5	3.51	79.59	2.15	R5
C12	D9	5.3	99.92	39.14	6.00	Dual
	E4	5.3	99.09	67.85	1.48	Dual
	F8	43.2	0.41	97.86	0.06	R5
C16	D10	1.7	52.21	37.72	0.17	Dual
	B7	16.6	0.08	104.19	0.05	R5
C21	B1	5.0	0.08	104.19	0.05	R5
	B3	4.0	0.18	62.81	0.14	R5
C25	B2	0.2	98.79	56.84	0.23	Dual
	D1	5.0	0.05	96.29	0.08	R5
	E12	5.0	0.07	95.85	0.44	R5
C27	D1	0.2	80.77	57.49	0.30	Dual
	F4	1.8	22.37	92.32	0.50	Dual
C28	D9	1.7	62.16	33.30	0.37	Dual
	F3	1.9	76.52	71.27	0.70	Dual
P04	B6	6.0	0.12	89.75	0.08	R5
	E12	41.2	3.03	85.81	2.64	R5
	G6	10.2	2.03	83.84	1.94	R5
P05	A10	7.0	6.52	88.10	7.46	R5
	B8	7.0	4.48	86.71	4.70	R5
P06	D10	16.9	0.26	62.59	0.28	R5
	D12	16.9	0.35	92.78	0.25	R5